ClinicalTrials.Veeva

Menu

Effects of Nitrous Oxide: A Dose-Response Analysis - 5

The University of Chicago logo

The University of Chicago

Status

Completed

Conditions

Opioid-Related Disorders
Substance-Related Disorders

Treatments

Drug: 30% N2O
Drug: 10% N2O
Drug: 20% N2O
Drug: 40% N2O

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT00000253
NIDA-08391-5
R01DA008391 (U.S. NIH Grant/Contract)
R01-08391-5

Details and patient eligibility

About

The purpose of this study is to conduct experiments to examine subjective and reinforcing effects of nitrous oxide. Mood altering and psychomotor effects will be tested on non-drug abusers and preference procedures will be used to assess reinforcing effects. To examine the subjective, psychomotor, and reinforcing effects of nitrous oxide in healthy volunteers. This is a dose-response analysis.

Enrollment

16 patients

Sex

All

Ages

21 to 37 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Please contact site for information.

Trial design

16 participants in 4 patient groups

Placebo + 10% N2O
Active Comparator group
Description:
0% N2O inhaled during psychomotor testing, 10% N2O inhaled during psycho motor testing, then subject's choice of the 2.
Treatment:
Drug: 10% N2O
Placebo + 20% N2O
Active Comparator group
Description:
Placebo inhaled during psychomotor testing, 20% N2O inhaled during psychomotor testing, then subject's choice of the 2.
Treatment:
Drug: 20% N2O
Placebo + 30% N2O
Active Comparator group
Description:
Placebo inhaled during psychomotor testing, 30% N2O inhaled during psychomotor testing, then subject's choice of the 2.
Treatment:
Drug: 30% N2O
Placebo + 40% N2O
Active Comparator group
Description:
Placebo inhaled during psychomotor testing, 40% N2O inhaled during psychomotor testing, then subject's choice of the 2.
Treatment:
Drug: 40% N2O

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems